Somapacitan
Also known as: NNC0195-0092, NNC9204-1706, Sogroya, Somapacitan, somapacitan-beco
Source Somapacitan at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Somapacitan (brand name Sogroya) is a long‑acting, albumin‑binding growth hormone analog administered once weekly by subcutaneous injection for treatment of adult growth hormone deficiency.
Mechanism of Action
Selective agonist of the growth hormone receptor, stimulating IGF-1 production and downstream anabolic effects
Routes of Administration
Goals & Uses
- Increase IGF-1 levelsBiomarkerHigh
- Improve body compositionMusculoskeletalHigh
- Reduce cardiovascular risk factorsCardiovascularModerate
- Improvement of quality of life in GHDPatient Reported OutcomesModerate
- Treatment of adult growth hormone deficiency (AGHD)Endocrinology / Hormone ReplacementHigh
- Treatment of pediatric growth hormone deficiencyEndocrinology / GrowthHigh
- Enhance quality of lifePatient ReportedModerate
- Improvement of body composition (lean mass / fat mass)Metabolic / Body CompositionHigh
Contraindications
- Active malignancyOncologyHighUse caution or avoid depending on agent and context
- Acute critical illnessCritical CareHigh
- Closed epiphyses with Prader-Willi syndrome and obesity/respiratory impairmentGenetic/RespiratoryHigh
- PregnancyPopulationModeratePotential fetal risk or insufficient safety data
- Diabetic retinopathyOphthalmologyModerate
- Hypersensitivity to somapacitan or excipientsAllergy / ImmunologyHigh
Adverse Effects
- EdemaFluid BalanceUncommonSwelling from fluid retention
- Peripheral edemaFluid BalanceCommonSwelling of the arms or legs
- HyperglycemiaMetabolicUncommonAbnormally high blood glucose
- Injection site reactionsLocalCommon
- HeadacheNeurologicCommonPain in the head or upper neck
- Intracranial hypertensionNeurologicalRare
- ArthralgiaMusculoskeletalUncommonJoint pain
- Hyperglycemia / insulin resistanceMetabolic / EndocrineUncommon
- Arthralgia / myalgiaMusculoskeletalCommon
Drug Interactions
- InsulinModerateMay increase risk of low blood sugar
- GlucocorticoidsLow
- Cytochrome P450-metabolized drugs (e.g., cyclosporine, sex steroids, anticonvulsants)Low
- Insulin / Oral antidiabeticsModerate
- Oral estrogenLow
Population Constraints
- PregnancyReproductive SafetyRelative
- History of malignancyOncologyRelative
- Pediatric patientsAgeRelative
- Diabetes mellitusMetabolicRelative
- Pediatric patients < 2 yearsAgeRelative
- Pregnant womenReproductiveRelative
Regulatory Status
- European UnionApprovedApproved: Adult growth hormone deficiencyApproved 2021.
- United StatesApprovedApproved: Adult growth hormone deficiencyApproved 2020; once‑weekly subcutaneous injection.
- United KingdomApprovedApproved: Adult growth hormone deficiencyApproved under MHRA.
Approved by FDA (2020) and EMA (2021) for adult GH deficiency; not approved for pediatric use.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Somapacitan?
Somapacitan (brand name Sogroya) is a long‑acting, albumin‑binding growth hormone analog administered once weekly by subcutaneous injection for treatment of adult growth hormone deficiency.
What is Somapacitan used for?
Somapacitan is educationally associated with: Increase IGF-1 levels, Improve body composition, Reduce cardiovascular risk factors, Improvement of quality of life in GHD, Treatment of adult growth hormone deficiency (AGHD), Treatment of pediatric growth hormone deficiency, Enhance quality of life, Improvement of body composition (lean mass / fat mass). Educational only — not medical advice.
How is Somapacitan administered?
Recorded routes of administration: Subcutaneous.
What are the potential side effects of Somapacitan?
Reported adverse effects include: Edema, Peripheral edema, Hyperglycemia, Injection site reactions, Headache, Intracranial hypertension, Arthralgia, Hyperglycemia / insulin resistance, Arthralgia / myalgia. This list is not exhaustive — consult a qualified clinician.
Who should avoid Somapacitan?
Recorded contraindications: Active malignancy, Acute critical illness, Closed epiphyses with Prader-Willi syndrome and obesity/respiratory impairment, Pregnancy, Diabetic retinopathy, Hypersensitivity to somapacitan or excipients. Consult a qualified clinician before use.